Hortensia De la Corte-Rodriguez

Osteoporosis, a widespread skeletal disorder with a substantial economic burden, is characterized by reduced bone density, resulting in increased fracture risk. Sclerotin inhibition with romosozumab (ROMO) represents a new therapeutic paradigm for the treatment of postmenopausal osteoporosis. We conducted a narrative review of the literature on ROMO’s role in osteoporosis treatment. ROMO has a unique dual effect of increasing bone formation (anabolic action) and decreasing bone resorption. It is a humanized monoclonal antibody injected monthly (210 mg subcutaneously once every four weeks for 12 months) that significantly increases lumbar spine, total hip, and femoral neck bone mineral density (BMD) compared with placebo, alendronate, and teriparatide at 6 and 12 months.